Natriuretic peptide receptor a as a novel anticancer target.

Natriuretic peptide receptor a as a novel anticancer target. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Natriuretic peptide receptor a as a novel anticancer target. Abstract Text:

Xiaoyuan Kong,Xiaoqin Wang,Weidong Xu,Sumita Behera,Gary Hellermann,Arun Kumar,Richard F Lockey,Subhra Mohapatra,Shyam S Mohapatra,Xiaoyuan Kong,Xiaoqin Wang,Weidong Xu,Sumita Behera,Gary Hellermann,Arun Kumar,Richard F Lockey,Subhra Mohapatra,Shyam S Mohapatra,

The receptor for atrial natriuretic peptide (ANP), natriuretic peptide receptor A (NPRA), is expressed in cancer cells, and natriuretic peptides have been implicated in cancers. However, the direct role of NPRA signaling in tumorigenesis remains elusive. Here, we report that NPRA expression and signaling is important for tumor growth. NPRA-deficient mice showed significantly reduced antigen-induced pulmonary inflammation. NPRA deficiency also substantially protected C57BL/6 mice from lung, skin, and ovarian cancers. Furthermore, a nanoparticle-formulated interfering RNA for NPRA attenuated B16 melanoma tumors in mice. Ectopic expression of a plasmid encoding NP73-102, the NH(2)-terminal peptide of the ANP prohormone, which down-regulates NPRA expression, also suppressed lung metastasis of A549 cells in nude mice and tumorigenesis of Line 1 cells in immunocompetent BALB/c mice. The antitumor activity of NP73-102 was in part attributed to apoptosis of tumor cells. Western blot and immunohistochemistry staining indicated that the transcription factor, nuclear factor-kappaB, was inactivated, whereas the level of tumor suppressor retinoblastoma protein was up-regulated in the lungs of NPRA-deficient mice. Furthermore, expression of vascular endothelial growth factor was down-regulated in the lungs of NPRA-deficient mice compared with that in wild-type mice. These results suggest that NPRA is involved in tumor angiogenesis and represents a new target for cancer therapy.

Natriuretic peptide receptor a as a novel anticancer target. Publishing Authors By Initials

X Kong,X Wang,W Xu,S Behera,G Hellermann,A Kumar,RF Lockey,S Mohapatra,SS Mohapatra,X Kong,X Wang,W Xu,S Behera,G Hellermann,A Kumar,RF Lockey,S Mohapatra,SS Mohapatra,

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Natriuretic peptide receptor a as a novel anticancer target. Journal Published:

PUBLICATION TYPE: Research Support, U.S. Gov't,

Journal: Cancer research

VOLUME: 68

Page Numbers: 249-56

Journal Abbreviation: Cancer Res.

ISSN: 1538-7445

DAY: 1

MONTH: Jan

YEAR: 2008

Natriuretic peptide receptor a as a novel anticancer target. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 2984705

Natriuretic peptide receptor a as a novel anticancer target. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Natriuretic peptide receptor a as a novel anticancer target. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Natriuretic peptide receptor a as a novel anticancer target.

AFFILIATION: Joy McCann Culverhouse Airway Disease and Nanomedicine Research Center, Allergy and Immunology Division, Department of Internal Medicine, University of South Florida College of Medicine, Tampa, FL 33612, USA.

Country: United States

AGENCY: United States NHLBI

GRANT: R01-5HL71101A2

ACRONYM: HL

MEDLINETA: Cancer Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Natriuretic peptide receptor a as a novel anticancer target Related Publications

• Application of DNA-based methods in typing Vibrio cholerae strains.
• Characterization and susceptibility patterns of clinically important Enterococcus species in eastern Nepal.
• Chitosan nanoparticle-mediated gene transfer.
• Chorea gravis.
• Correlation between CD4 counts of HIV patients and enteric protozoan in different seasons - An experience of a tertiary care hospital in Varanasi (India).
• Curcumin prevents human dendritic cell response to immune stimulants.
• Development of hyaluronic acid-Fe2O3 hybrid magnetic nanoparticles for targeted delivery of peptides.
• Folate receptor-mediated cancer cell specific gene delivery using folic acid-conjugated oligochitosans.
• High-resolution computed tomography in Mycobacterium avium complex disease: one step forward, two steps back.
• Interaction between medical practitioners & pharmaceutical industry.
• Natriuretic peptide receptor a as a novel anticancer target.
• Observations on carbapenem resistance by minimum inhibitory concentration in nosocomial isolates of Acinetobacter species: an experience at a tertiary care hospital in North India.
• Polymerase chain reaction engineering.
• Prevalence of methicillin resistant staphylococcus aureus in a tertiary referral hospital in eastern Uttar Pradesh.
• Prevention of airway inflammation with topical cream containing imiquimod and small interfering RNA for natriuretic peptide receptor.
• Proton Decay and Flavor Violating Thresholds in SO(10) Models.
• Role of natriuretic peptide signaling in modulating asthma and inflammation.
• Sputum conversion at the end of intensive phase treatment of pulmonary tuberculosis patients with diabetes mellitus or HIV infection.
• Superiority of dat over elisa as a diagnostic and seroepidemiological tool for the diagnosis of Indian kala-azar.
• Thiolated chitosan nanoparticles enhance anti-inflammatory effects of intranasally delivered theophylline.
• Thiolated chitosan/DNA nanocomplexes exhibit enhanced and sustained gene delivery.
• Ultrasensitive detection of cortisol with enzyme fragment complementation technology using functionalized nanowire.
• Unigene derived microsatellite markers for the cereal genomes.
• Use of quinolones: one step forward, a few steps back.